PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises

Cancer Treatment Reviews

Volumn 41, Issue 2, 2015, Pages 114-121

  Massari, F ^a   Santoni, M ^b   Ciccarese, C ^a   Santini, D ^c   Alfieri, S ^d   Martignoni, G ^a   Brunelli, M ^a   Piva, F ^b   Berardi, R ^b   Montironi, R ^b   Porta, C ^e   Cascinu, S ^b   Tortora, G ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Immunotherapy; PD 1; PDL 1; Renal cell carcinoma

Indexed keywords

AMP 224; ANGIOGENESIS INHIBITOR; BLOCKING ANTIBODY; BMS 936559; CD137 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; IPILIMUMAB; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADOPTIVE CELL TRANSFER; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER THERAPY; CELL TRANSFER; DISEASE ASSOCIATION; DRUG MECHANISM; HUMAN; IMMUNE SYSTEM; KIDNEY CARCINOMA; LYMPHOCYTE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ANTAGONISTS AND INHIBITORS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CANCER GRADING; CARCINOMA, RENAL CELL; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DOWN REGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY NEOPLASMS; METABOLISM; PATHOLOGY; PROCEDURES; PROGNOSIS; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84921779027     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.12.013     Document Type: Review

References (72)

1. Yang J.C., Childs R. Immunotherapy for renal cell cancer. J Clin Oncol 2006, 24:5576-5583.
2. Porta C., Bonomi L., Lillaz B., Paglino C., Rovati B., Imarisio I., et al. Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. Anticancer Res 2007, 27:165-173.
3. Noessner E., Brech D., Mendler A.N., Masouris I., Schlenker R., Prinz P.U. Intratumoral alterations of dendritic-cell differentiation and CD8(+) T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma. Oncoimmunology 2012, 1:1451-1453.
4. Pardoll D.M. Blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12:252-264.
5. Ishida Y., Agata Y., Shibahara K., Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992, 11:3887-3895.
6. Nirschl C.J., Drake C.G. Molecular pathways: co-expression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res 2013, 19:4917-4924.
7. MacFarlane A.W., Jillab M., Plimack E.R., Hudes G.R., Uzzo R.G., Litwin S., et al. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res 2014 Apr, 2(4):320-331.
8. Keir M.E., Francisco L.M., Sharpe A.H. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol 2007, 19:309-314.
9. Ghiotto M., Gauthier L., Serriari N., Pastor S., Truneh A., Nunès J.A., et al. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int Immunol 2010, 22(8):651-660.
10. Topalian S.L., Drake C.G., Pardoll D.M. Targeting the PD-1/B7H1 (PD-L1) pathway to activate antitumor activity. Curr Opin Immunol 2012, 24:207-212.
11. Thompson R.H., Dong H., Kwon E.D. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 2007, 13:709s-715s.
12. Callea M., Genega E.M., Gupta M., Cheng S., Fay A.P., Song J., et al. PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases. J Clin Oncol 2014, 32. 5s, Suppl.; abstr 4585.
13. Choueiri T.K., Fay A.P., Gray K.P., Callea M., Ho T.H., Albiges L., et al. PD-L1 expression in non-clear cell renal cell carcinoma. Ann Oncol 2014, pii: mdu445. [Epub ahead of print].
14. Jilaveanu L.B., Shuch B., Zito C.R., Parisi F., Barr M., Kluger Y., et al. PD-L1 expression in clear cell renal cell carcinoma: an analysis of nephrectomy and sites of metastases. J Cancer 2014, 5(3):166-172.
15. Thompson R.H., Kuntz S.M., Leibovich B.C., Dong H., Lohse C.M., Webster W.S., et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006, 66(7):3381-3385.
16. Frigola X., Inman B.A., Lohse C.M., Krco C.J., Cheville J.C., Thompson R.H., et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res 2011, 17(7):1915-1923.
17. Ning H., Shao Q.Q., Ding K.J., Gao D.X., Lu Q.L., Cao Q.W., et al. Tumor-infiltrating regulatory T cells are positively correlated with angiogenic status in renal cell carcinoma. Chin Med J (Engl) 2012, 125:2120-2125.
18. Adotevi O., Pere H., Ravel P., Haicheur N., Badoual C., Merillon N., et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010, 33:991-998.
19. Desar I.M., Jacobs J.H., Hulsbergen-vandeKaa C.A., Oyen W.J., Mulders P.F., van der Graaf W.T., et al. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int J Cancer 2011, 129:507-512.
20. Huijts C.M., Santegoets S.J., van den Eertwegh A.J., Pijpers L.S., Haanen J.B., de Gruijl T.D., et al. Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer. BMC Cancer 2011, 11:505.
21. Kang M.J., Kim K.M., Bae J.S., Park H.S., Lee H., Chung M.J., et al. Tumor-infiltrating PD1-positive lymphocytes and FoxP3-positive regulatory T cells predict distant metastatic relapse and survival of clear cell renal cell carcinoma. Transl Oncol 2013, 6(3):282-289.
22. Chen X., Fosco D., Kline D.E., Meng L., Nishi S., Savage P.A., et al. PD-1 regulates extrathymic regulatory T-cell differentiation. Eur J Immunol 2014, 44(9):2603-2616.
23. Eckl J., Buchner A., Prinz P.U., Riesenberg R., Siegert S.I., Kammerer R., et al. Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging. J Mol Med 2012, 90:55-66.
24. Huang Y., Wang Y., Li Y., Guo K., He Y. Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2. J Cancer Res Clin Oncol 2011, 137:829-837.
25. Choueiri T.K., Figueroa D.J., Liu Y., Gagnon R.C., Deen K.C., Carpenter C., et al. Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis. J Clin Oncol 2014, 32(4). abstr 416.
26. Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., Sharfman W.H., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmodynamics, and immunologic correlates. J Clin Oncol 2010, 28:3167-3175.
27. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
28. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
29. Cho D.C., Sosman J.A., Sznol M., Gordon M.S., Hollebecque A., Hamid O., et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013, 31(Suppl.):4505.
30. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369(2):122-133.
31. Topalian S.L., Sznol M., McDermott D.F., Kluger H.M., Carvajal R.D., Sharfman W.H., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014, 32(10):1020-1030.
32. Motzer R.J., Rini B.I., McDermott D.F., Redman B.G., Kuzel T., Harrison M.R., et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2014, pii: JCO.2014.59.0703. [Epub ahead of print].
33. Choueiri T.K., Fishman M.N., Escudier B.J., Kim J.J., Kluger H.M., Stadler W.M., et al. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): biomarker-based results from a randomized clinical trial. J Clin Oncol 2014, 32. 5s, Suppl.; abstr 5012.
34. Patnaik A., Kang S.P., Tolcher A.W., Rasco D.W., Papadopoulos K.P., Beeram M., et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. J Clin Oncol 2012, 30. Suppl.; abstr 2512.
35. Infante J.R., Powderly J.D., Burris H.A., Kittaneh M., Grice J.H., Smothers J.F., et al. Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor. J Clin Oncol 2013, 31. abstr 3044.
36. Segal N.H., Antonia S.J., Brahmer J.R., Maio M., Blake-Haskins A., Li X., et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol 2014, 32. 5s, abstr TPS3120.
37. Santoni M., Rizzo M., Burattini L., Farfariello V., Berardi R., Santoni G., et al. Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicity. Recent Pat Antiinfect Drug Discov 2012, 7:104-110.
38. Porta C., Paglino C., Imarisio I., Ganini C., Pedrazzoli P. Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies?. J Cancer 2011, 2:333-338.
39. Lin J.C., Liu C.L., Lee J.J., Liu T.P., Ko W.C., Huang Y.C., et al. Sorafenib induces autophagy and suppresses activation of human macrophage. Int Immunopharmacol 2013, 15:333-339.
40. Toge H., Inagaki T., Kojimoto Y., Shinka T., Hara I. Angiogenesis in renal cell carcinoma: the role of tumor-associated macrophages. Int J Urol 2009, 16:801-807.
41. Ko J.S., Rayman P., Ireland J., Swaidani S., Li G., Bunting K.D., et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010, 70:3526-3536.
42. Amin A., Plimack E.R., Infante J.R., Ernstoff M.S., Rini B.I., McDermott D.F., et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2014, 32. 5s, Suppl.; abstr 5010.
43. Taube J.M., Anders R.A., Young J.D., Xu H., Sharma R., McMiller T.L., et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012, 4. 127ra37.
44. Gajewski T.F., Louahed J., Brichard V.G. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 2010, 16:399-403.
45. Sharma P., Wagner K., Wolchok J.D., Allison J.P. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011, 11:805-812.
46. Escudier B. Emerging immunotherapies for renal cell carcinoma. Ann Oncol 2012, 23(8):viii35-viii40.
47. Rosenblatt J., McDermott D.F. Immunotherapy for renal cell carcinoma. Hematol Oncol Clin North Am 2011, 25:793-812.
48. Flörcken A., Kopp J., Movassaghi K., et al. Allogeneic partially HLA-matched dendritic cells (DC) as a vaccine in metastatic renal cell cancer (mRCC): final analysis of a clinical phase I/II study. J Clin Oncol 2012, 30(Suppl.). abstract e15053.
49. Argos Therapeutics. New phase 2 data showing Arcelis™ immunotherapy AGS-003 in combination with sunitinib improves progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC). http://www.argostherapeutics.com.
50. Wood C., Srivastava P., Bukowski R., Lacombe L., Gorelov A.I., Gorelov S., et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008, 372:145-154.
51. Harrop R., Shingler W.H., McDonald M., Treasure P., Amato R.J., Hawkins R.E., et al. MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Cancer Immunol Immunother 2011, 60:829-837.
52. Reinhardt C., Zdrojowy R., Szczylik C., et al. Results of a randomized phase II study investigating multipeptide vaccination with IMA901 in advanced renal cell carcinoma (RCC). J Clin Oncol 2010, 28. abstract 4529.
53. Chambers C.A., Kuhns M.S., Egen J.G., Allison J.P. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001, 19:565-594.
54. Yang J.C., Hughes M., Kammula U., Royal R., Sherry R.M., Topalian S.L., et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007, 30:825-830.
55. Hammers H.J., Plimack E.R., Infante J.R., Ernstoff M.S., Rini B.I., McDermott D.F., et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2014, 32. 5s, Suppl.; abstr 4504.
56. Attia P., Maker A.V., Haworth L.R., Rogers-Freezer L., Rosenberg S.A. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005, 28:582-592.
57. Atchison E., Eklund J., Martone B., Wang L., Gidron A., Macvicar G., et al. A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC). J Immunother 2010, 33:716-722.
58. Casati C., Camisaschi C., Rini F., Arienti F., Rivoltini L., Triebel, et al. Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity. Cancer Res 2006, 66:4450-4460.
59. Brignone C., Escudier B., Grygar C., Marcu M., Triebel F. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 2009, 15:6225-6231.
60. Rosenberg S.A., Lotze M.T., Yang J.C., Topalian S.L., Chang A.E., Schwartzentruber D.J., et al. Prospective randomized trial of highdose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993, 85:622-632.
61. Tomita Y., Katagiri A., Saito K., Imai T., Saito T., Tanikawa T., et al. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results. Int J Urol 1998, 5:16-21.
62. Wersall P., Mellstedt H. Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN. Med Oncol 1995, 12:69-77.
63. Rosenberg S.A., Lotze M.T., Muul L.M., Leitman S., Chang A.E., Ettinghausen S.E., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985, 313:1485-1492.
64. Bukowski R.M., Sharfman W., Murthy S., Rayman P., Tubbs R., Alexander J., et al. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res 1991, 51:4199-4205.
65. Kradin R.L., Kurnick J.T., Lazarus D.S., et al. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1989, 1:577-580.
66. Dillman R., Schiltz P., DePriest C., Preffer F.I., Dubinett S.M., Pinto C.E., et al. Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancer. Cancer Biother Radiopharm 2004, 19:730-737.
67. Figlin R.A., Thompson J.A., Bukowski R.M., Vogelzang N.J., Novick A.C., Lange P., et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999, 17:2521-2529.
68. Goedegebuure P.S., Douville L.M., Li H., Richmond G.C., Schoof D.D., Scavone M., et al. Adoptive immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol 1995, 13:1939-1949.
69. Thiounn N., Mathiot C., Flam T., Tartour E., Peyret C., Joyeux I., et al. CD4 TIL (Tumor Infiltrating Lymphocytes) induce complete response in patients treated with IL-2 (Interleukin-2). Preliminary study. J Urol (Paris) 1994, 100:185-188.
70. Gommersall L., Hayne D., Lynch C., Joseph J.V., Arya M., Patel H.R. Allogeneic stem-cell transplantation for renal-cell cancer. Lancet Oncol 2004, 5:561-567.
71. Li B., VanRoey M., Wang C., Chen T.H., Korman A., Jooss K. Antiprogrammed death-1 synergizes with granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res 2009, 15(5):1623-1634.
72. Vinay D.S., Kwon B.S. Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 2012, 11:1062-1070.